Last reviewed · How we verify
Interferon-β 1a
At a glance
| Generic name | Interferon-β 1a |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 (PHASE2)
- An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial (PHASE2)
- Interferon Beta 1a in Hospitalized COVID-19 Patients (PHASE4)
- Umifenovir in Hospitalized COVID-19 Patients (PHASE4)
- Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (PHASE3)
- Therapy Optimization in Multiple Sclerosis (MS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon-β 1a CI brief — competitive landscape report
- Interferon-β 1a updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI